Postmenopausal osteoporosis is a condition that weakens bones to the point that they become brittle, fragile, and vulnerable to fractures. It occurs in women after menopause when the ovaries gradually produce less estrogen, resulting in a dramatic increase in bone loss. Some key symptoms of postmenopausal osteoporosis include loss of height over time, a stooped posture, and fractured bones that occur with little or no trauma. It can be difficult to diagnose without x-rays since many people may not experience any signs or symptoms until they have a fracture. The global postmenopausal osteoporosis market is estimated to be valued at US$ 4747.9 Mn in 2023 and is expected to exhibit a CAGR of 67.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The key opportunity for increased treatment lies in raising awareness about postmenopausal osteoporosis screening and management. Many women remain unaware that they are at risk for osteoporosis and do not seek medical attention until they experience a fracture. However, fractures associated with osteoporosis can significantly impact quality of life and mobility. Greater public education efforts are needed to inform women about recommended bone density scans after menopause and the many effective pharmaceutical and lifestyle treatment options available. This could help more women receive a diagnosis and start preventative treatment plans early before complications arise. Wider screening would capture more patients and boost adherence to long-term management regimens, driving higher market demand for osteoporosis drugs and devices over the forecast period. Porter's Analysis Threat of new entrants: The threat of new entrants in the postmenopausal osteoporosis market is low due to the high R&D costs and established brands controlling majority of the market share. Bargaining power of buyers: The bargaining power of buyers is high owing to availability of generic drugs and treatment alternatives. Bargaining power of suppliers: The bargaining power of suppliers is moderate due to presence of many suppliers and brands in the market. Threat of new substitutes: Threat of substitutes is moderate as alternative treatment options like exercise and calcium intake are available. Competitive rivalry: Intense due to many established brands competing for larger market share. SWOT Analysis Strength: Wide range of treatment options available including bisphosphonates, selective estrogen receptor modulators (SERMs), monoclonal antibodies, and anabolic agents. Rising awareness regarding osteoporosis management. Weakness: High costs associated with branded drugs and surgical procedures. Occurrence of side effects with long term usage of drugs. Opportunity: Growth in geriatric population prone to osteoporosis. Expanding healthcare infrastructure and spending in emerging nations. Threats: Patent expirations of blockbuster drugs. Stringent regulations for new drug approvals. Key Takeaways Global Postmenopausal Osteoporosis Market Size is expected to witness high growth due to rising geriatric population and postmenopausal women prone to osteoporosis. Regionally, North America is expected to dominate the market owing to developed healthcare infrastructure, high awareness, and higher healthcare spending. However, Asia Pacific is likely to emerge as the fastest growing region due to growing economy, rise in healthcare expenditure, and increasing focus on women's health. Key players operating in the postmenopausal osteoporosis market are IBM Research, Inc., Knowm Inc., Intel Corp., BrainChip Holdings Ltd., General Vision Inc., HRL Laboratories, LLC, Qualcomm Technologies Inc., and Hewlett Packard Labs. Most companies focus on developing novel drugs with improved safety profiles and new drug delivery mechanisms. Partnerships and acquisitions are some of the strategies adopted by these players to consolidate their position in the market. Get More Insights on this Topic- https://www.rapidwebwire.com/postmenopausal-osteoporosis-market-forecast-analysis-and-trends/
0 Comments
Sports nutrition products such as sports drinks, nutrition supplements, and functional food provide necessary nutrients and enhance physical performance. Sports nutrition products help in improving muscle mass, strength, and endurance. Sports drinks hydrate the body during physical exercise by replacing electrolytes and carbohydrates. Nutrition supplements such as vitamins, proteins, minerals, and fatty acids provide required nutrients. Functional food including sports bars provides nutrition on-the-go. With growing popularity of fitness activities and increasing health awareness among consumers, demand for sports nutrition products is rising significantly. The global Sports Nutrition Market is estimated to be valued at US$ 46.83 Bn in 2023 and is expected to exhibit a CAGR of 3.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The increasing health awareness among consumers is driving the growth of the sports nutrition market. According to a survey, over 60% of American adults engage in some form of physical exercises weekly. Furthermore, rising obesity rates globally are encouraging people to adopt healthy lifestyles including exercise and consumption of nutritional food and beverages. Sports nutrition products help in weight management and maintaining fitness goals. As consumers are focusing more on preventive healthcare, the demand for nutrition-rich food and beverages is growing. Sports nutrition products provide necessary nutrients and fuel the body with energy and endurance during workouts. The trend of fitness combined with the increasing health awareness is expected to continue driving the demand for high-quality sports nutrition products over the forecast period. Sports nutrition manufacturers are anticipated to leverage this opportunity through innovative product launches catering to the changing consumer preferences. Porter’s Analysis Threat of new entrants: High capital requirements and existing strong brand loyalty towards established players in sports nutrition market pose entry barriers for new players. Bargaining power of buyers: Buyers have moderate bargaining power due to availability of substitute products and brands. Bargaining power of suppliers: Suppliers have low to moderate bargaining power due to availability of substitute raw materials. Threat of new substitutes: Threat of substitution is moderate as protein supplies, vitamins, minerals and others are available from other industries also but with changing lifestyle and health awareness, demand for sports nutrition products is growing. Competitive rivalry: The global sports nutrition market is highly fragmented and competitive with major players fiercely competing on the basis of product quality and pricing. SWOT Analysis Strength: Sports nutrition products help improve athletes’ performance, accelerate muscle recovery and fulfill daily nutritional needs. Weakness: High prices of natural and protein rich sports nutrition products limit their adoption. Opportunity: Rising health consciousness, disposable income and number of health clubs/gyms in emerging nations provides growth opportunities. Threats: Stringent regulations on advertising claims of sports supplements and easy availability of substitutes pose threats. Key Takeaways Global Sports Nutrition Market Demand is expected to witness high growth. The growing participation in sports and fitness activities due to increasing health awareness globally is driving the market growth. North America dominates the global sports nutrition market currently. High disposable incomes and growing adoption of active lifestyles in countries like the US and Canada has contributed to North America’s leading position. Asia Pacific is projected to be the fastest growing region in the forecast period due to rising health consciousness, growing middle class population and increasing availability of various sports nutrition products in countries like India, China and Japan. Key players operating in the sports nutrition market are Novartis, Pfizer, Roche, Sanofi, Merck &Co., AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Gilead Sciences, and others. Novartis and Pfizer are the global leaders in pharmaceuticals and dominate the sports nutrition and supplements market as well through brands like Boost and Ensure. Get More Insights on this Topic= https://www.dailyprbulletin.com/sports-nutrition-market-size-share-and-value-growth/ West Nile virus (WNV) is a mosquito-borne flavivirus commonly found in Africa, Eastern Europe, West Asia, and the Middle East. Most people infected with West Nile virus experience no symptoms, but the virus can cause symptoms ranging from mild, such as fever, headache, and muscle ache, to severe neurological illnesses. Therapeutics targeting West Nile virus is aimed at treating symptomatic infections. Vaccines are also being developed to prevent the infection. The global West Nile virus therapeutics market accounts for a small fraction of the overall pharmaceutical industry given the low infection rates in most parts of the world. However, the market provides significant growth opportunities owing to increasing government support for research and development of new drugs and vaccines targeting WNV. The global West Nile Virus market is estimated to be valued at US$ 634.8 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: The increasing government support for research and development is estimated to drive the growth of the West Nile virus therapeutics market over the forecast period. For instance, the US government provides significant funding for WNV research through its National Institute of Allergy and Infectious Diseases. In 2021, the institute awarded grants worth over US$ 15 Mn supporting studies related to diagnostics, therapeutics, vaccines and other aspects of mosquito-borne viruses including West Nile virus. Such funding aids drug development programs at both academic institutions and biopharmaceutical companies. Additionally, the market is witnessing increasing private investment in development of new treatment options. Large pharmaceutical players are partnering with smaller biotech firms working on WNV programs. For example, in 2021 Takeda Pharmaceutical collaborated with Evotec to develop antiviral therapies targeting West Nile virus and other mosquito-borne viruses. Such partnerships help bolster advancement of treatment candidates currently in preclinical and clinical trial stages. SWOT Analysis Strength: The West Nile Virus Market has seen significant growth in research and development spending over the past decade. This has led to advancements in virus detection technologies and improved monitoring strategies. Several diagnostic kits and assays are now commercially available for early and accurate identification of the virus. Weakness: Currently, there is no vaccine approved for humans against West Nile Virus in the United States. Existing treatment options are supportive in nature and focus on managing symptoms. Developing a safe and effective vaccine poses several technical challenges due to the ability of the virus to replicate in mosquitoes and birds. Opportunity: With rising global incidence rates of West Nile Virus infections, especially in developing regions, there is a significant unmet need for preventive solutions. Countries in Asia, Africa, and Latin America represent lucrative growth opportunities. Advancements in viral vector-based vaccine platforms offer promise for the development of a viable prophylactic. Threats: Outbreaks are dependent on several environmental factors beyond human control like climate conditions, mosquito breeding patterns etc. Unpredictable disease pattern poses risks to forecasting commercial returns on R&D investments. Generic competition from low-cost manufacturers in the diagnostics segment once core patents expire can squeeze profits. Key Takeaways Global West Nile Virus Market Size is expected to witness high growth over the forecast period supported by rising disease incidence worldwide and ongoing research efforts towards developing effective vaccines and therapeutics. The market stood at $634.8 million in 2023 and is estimated to reach $1,090.1 million by 2030, expanding at a CAGR of 7.6%. North America currently dominates market share due to supportive regulatory environment and presence of major industry players. However, Asia Pacific is poised to emerge as the fastest growing regional market. Factors such as the tropical climate conducive for mosquito propagation, lack of effective prevention programs, and improving healthcare infrastructure are directing focus towards APAC. Key players operating in the West Nile Virus market are Sanofi, Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Johnson & Johnson, F. Hoffmann-La Roche, Novartis, Cipla, and Gilead Sciences. These companies primarily concentrate on vaccines and antiviral drugs to curb West Nile virus infections. Collaborations between public health organizations and private firms are also ongoing to strengthen monitoring and response activities. Get More Insights on this Topic https://www.marketwebjournal.com/west-nile-virus-market-growth-forecast-and-analysis/ Pharmaceuticals Are the Largest Segment Driving the Growth of the Estrogen Blockers Market11/17/2023 The global Estrogen Blockers Market is estimated to be valued at US$ 15.02 Bn in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Estrogen blockers are also known as anti-estrogens that help lower the level of estrogen in the body by binding to estrogen receptors and blocking the binding and action of estrogen. They are used to treat conditions like breast cancer, prostate cancer, endometriosis, osteoporosis by inhibiting the growth of cancer cells that require estrogen to grow. Market key trends: One of the key trends in the estrogen blockers market is the growing prevalence of breast cancer worldwide. As per WHO, breast cancer is the most common cancer in women, impacting 2.3 million women each year globally. Early detection and treatment along with use of estrogen blockers is crucial to manage the disease. This has significantly driven the demand for estrogen blocking drugs globally. SWOT Analysis Strength: SERMs have more favorable side effect and safety profiles as compared to complete estrogen blockers. They block estrogen action in breast and uterus while having estrogen agonist actions in other tissues. Weakness: Availability of alternative treatment options for conditions like breast cancer and osteoporosis. Opportunity: Rising incidence of hormone-dependent cancers worldwide offers potential growth opportunities. Threats: Patent expiries of major drugs may impact the market revenues of individual companies. Stiff competition from generic versions once patents expire. Key Takeaways Global Estrogen Blockers Market Size was valued at US$ 15.02 Bn in 2023 and is expected to witness high growth, exhibiting CAGR of 6.5% over the forecast period, due to increasing incidence of hormone-dependent cancers. Regional analysis: North America dominated the market with over 30% market share in 2023 due to rising breast cancer prevalence in the region. Asia Pacific is expected to witness fastest growth due to growing patient population, rising healthcare spending and increasing focus of global players. Key players operating in the estrogen blockers market are Pfizer Inc., Novartis AG, AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., Bristol Myers Squibb Company, Johnson & Johnson, Sanofi S.A., AbbVie Inc., GlaxoSmithKline plc. Some of the widely prescribed brands include tamoxifen (Nolvadex) and raloxifene (Evista). Read More- https://www.trendingwebwire.com/estrogen-blockers-market-value-inisghts-and-forecast/ |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
January 2024
Categories
All
|